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Objectives. The aim of this study was to investigate whether 
intracoronary infusion of dipyridamole r presents a suitable tool 
for preventing deterioration of left ventricular performance and 
hemodynamic function during percutaneous transluminal coro- 
nary angioplasty (PTCA). 
Background. Coronary angioplasty represents a suitable model 
for establishing myocardial ischemia in humans. Balloon inflation 
is usually accompanied bysignificant deterioration i left ventric- 
ular systolic and diastolic properties. A brief episode of ischemia 
followed by reperfusion, termed preconditioning, has been identi- 
fied as a mechanism for rendering the myocardium ore resistant 
to ischemia. Adenosine is considered an important mediator of 
preconditioning. Dipyridamole is an important drug that inter- 
feres with myocardial adenosine metabolism by inhibiting its 
cellular euptake. 
Methods. In 20 patients undergoing elective coronary angio- 
plasty of a major vessel, assessment of angiographic left ventric- 
ular performance and hemodynamic variables was performed 
before, during and after PTCA. Patients were randomly allocated 
to pretreatment with intracoronary infusion of dipyridamole 
before percutaneous transluminal coronary angioplasty (10 pa- 
tients) or conventional pretreatment without dipyridamole (10 
patients). 
Results. Dipyridamole pretreatment resulted in significant 
preservation fsystolic and diastolic left ventricular performance 
during percutaneous transluminal coronary angioplasty, as doc- 
umented by an unaffected global ejection fraction (vs. a deterio- 
ration of 29.2% with conventional pretreatment, p < 0.01) and an 
increment in diastolic stiffness of only 12.7% (vs. an increment of 
57.3% with conventional pretreatment, p < 0.01). Apart from one 
instance of coronary steal phenomenon, nosignificant side effects 
of dipyridamole infusion could be detected. 
Conclusions. It is concluded that intracoronary application of 
dipyridamole may result in the induction of myocardial precon- 
ditioning by improving systolic and diastolic ventricular perfor- 
mance during percutaneous transluminai coronary angioplasty, 
thereby potentially reducing the risk of the angioplasty procedure. 
(JAm Coil Cardiol 1996;28:1119-26) 
Preconditioning has been defined as a mechanism that renders 
hearts more resistant o ischemia (1-3) and reduces myocar- 
dial infarct size and complications (4,5). Preconditioning is 
established by a preceding episode of provocation (e.g., coro- 
nary occlusion, atrial pacing). Adenosine has been identified as 
a crucial substance in the induction and maintenance of 
preconditioning (6). However, some investigators doubt that 
myocardial protection as a result of preconditioning can be 
established in humans (7). 
Dipyridamole represents a well established medication that 
induces dilation of coronary arteries by inhibiting the degra- 
dation of adenosine. In the clinical setting, intravenous dipyr- 
idamole in a dosage of 0.5 mg/kg body weight allows the 
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quantification of coronary flow reserve (8). Side effects of 
intravenous dipyridamole include headache, tachycardia and 
hypotension (9). Intravenous administration is accompanied by
a high rate of plasma protein binding (10) of up to 99%, which 
might counteract a sufficient local cardiac effect (coronary 
circulation, myocardium, icrocirculation, interstitium). Intra- 
coronary dipyridamole administration might result in a higher 
local concentration, with consecutive r duction of side effects, 
potentiation ofcoronary flow and enhancement of local aden- 
osine concentration (11). 
A recently published study from our department (12) 
documented that intracoronary dipyridamole infusion induces 
a significant gain in tolerance to ischemia during percutaneous 
transluminal coronary angioplasty (PTCA), indicating that 
intracoronary dipyridamole might represent a determinant of
myocardial preconditioning. The purpose of the present study 
was to evaluate whether intracoronary dipyridamole infusion is 
accompanied by a reduction in systolic and diastolic dysfunc- 
tion (13) and augmentation of hemodynamic performance 
during PTCA. The data presented indicate that ventricular 
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Abbreviations and Acronyms 
dP/dt max = maximal rate of increase of left 
ventricular pressure 
dP/dt max/IP = dP/dt max at a developed pressure of 
40 mm Hg 
dP/dt rain - maximal rate of decline of left 
ventricular pressure 
dP/dV = diastolic stiffness 
ECG = electrocardiogram 
LVEDP = left ventricular end-diastolic pressure 
MNSER = mean normalized systolic ejection 
fraction 
P syst/ESV - systolic arterial blood pressure 
divided by end-systolic volume 
PTCA percutaneous transluminal coronary 
angioplasb' 
VCF = velocity of circumferential fiber 
shortening 
dysfunction during PTCA can be prevented by intracoronary 
dipyridamole. 
Methods 
Patients. Twenty patients undergoing elective PTCA were 
randomly selected to receive ither conventional pretreatment 
consisting of aspirin and heparin or additional pretreatment 
with dipyridamole before PTCA. Written informed consent 
was obtained from all patients. The investigator (B.E.S.) 
performing the PTCA was aware of the pretreatment admin- 
istered. Dipyridamole infusion was preferred to adenosine 
because of possible negative chronotropic and dromotropic 
(atrioventricular blockade) side effects of intracoronary aden- 
osine. Coronary angioplasty was performed according to the 
standard criteria of our department (14). Patient inclusion 
criteria included 1) stable angina pectoris; 2) isolated stenosis 
in the proximal two-thirds of a major coronary artery without 
angiographic evidence of collateral channels; 3) electrocardio- 
gram (ECG) with stable sinus rhythm and without signs of 
ischemia or bundle branch block; 4) primary successful balloon 
inflation resulting in residual stenosis <30%. 
Patients demonstrating local impairment of left ventricular 
function because of a history of myocardial infarction were 
only admitted if PTCA was performed in an artery supplying 
myocardium with normal ventricular performance. No patient 
had a history of diabetes mellitus or coronary artery bypass 
grafting. 
Angiography and PTCA. For left ventricular angiography 
and measurement of left ventricular and aortic pressures, a
pigtail catheter was placed through the left femoral artery, 
using fluid-filled catheter systems for measurement of phasic 
pressures. Coronary angiography and angioplasty were per- 
formed through the right femoral artery. After documentation 
of baseline hemodynamic variables, biplane angiography using 
the 30 ° left anterior oblique and 60 o right anterior oblique 
projections and coronary angiography were performed. All 
patients received intravenous heparin (15,000 IU) and aspirin 
(500 mg). In 10 patients, dipyridamole was infused in a dosage 
of 0.5 mg/kg body weight over 5 rain into the vessel undergoing 
PTCA. In this group, PTCA was initiated after reestablishment 
of baseline hemodynamic variables (mean time 233 _+ 10 s). 
Immediately before termination of PTCA, left ventricular 
angiography and measurement of left ventricular hemody- 
namic variables were again performed. Angioplasty was termi- 
nated if severe angina pectoris or significant cardiac arrhyth- 
mias occurred, according to the judgment of the investigator. A
maximal balloon inflation time of 300 s was allowed in patients 
with little or no pain. The investigation was completed after 
left ventricular angiography and final measurement of left 
ventricular hemodynamic variables were performed for the 
third time. 
Hemodynamic variables. Using commercial software 
(Kontron Cardio 500) end-diastolic and end-systolic volumes 
and global left ventricular ejection fraction were calculated, 
and quantitative coronary angiography measuring % diameter 
stenosis of the target vessel and non-PTCA arteries was 
performed by an investigator (U.E.H.) with no knowledge of 
the pretreatment administered. The angiogram demonstrating 
the largest end-diastolic volume, coinciding with the R wave of 
the surface ECG, was considered to demonstrate nd of 
diastole. The first angiogram after closure of the aortic valve 
was considered to demonstrate he end of systole, synchronous 
with the dicrotic notch of the aortic pressure curve. For 
assessment of regional left ventricular function, 10 perpendic- 
ular chords (ml to ml0) were constructed (15). Fractional 
myocardial shortening was calculated for each chord. For 
further analysis, mean fractional shortening of ischemic myo- 
cardium was calculated and compared with mean fractional 
shortening of nonjeopardized myocardium. Furthermore, the 
velocity of circumferential fiber shortening (VCR), mean 
normalized systolic ejection rate (MNSER), tension time index 
and the index of contractility, were evaluated. The VCR was 
calculated as EDD - ESD/EDD x LVET; MNSER as 
EF/LVET; and the index of contractility as arterial systolic 
pressure divided by end-systolic volume (P syst/ESV), where 
EDD = end-diastolic diameter; ESD = end-systolic diameter; 
and LVET = left ventricular ejection time. Using the record- 
ings of left ventricular and aortic pressures, we determined the 
following isovolumetric ndexes: maximal rate of increase of 
left ventricular pressure (dP/dt max); maximal rate of decline 
of left ventricular pressure (dP/dt min); dP/dt max at a 
developed pressure of 40 mm Hg (dP/dt max/IP). Additionally, 
left ventricular end-diastolic pressure (LVEDP), diastolic stiff- 
ness (dP/dV) and end-systolic and end-diastolic wall stress 
were quantified. End-systolic wall stress was calculated accord- 
ing to Laplace and defined as T = p x r/2d, where p = systolic 
left ventricular pressure minus LVEDP; r = internal radius of 
the left ventricle; d = wall thickness of the left ventricle in a 
segment of the anterior wall 4 cm long. End-diastolic wall 
stress was defined analogously, with p = LVEDP. The surface 
ECG was recorded, and RR interval measurement was per- 
formed during the complete diagnostic and interventional 
JACC Vol. 28, No. 5 STRAUER ET AL. 1121 
November 1. 1996:1119-26 DIPYRIDAMOLE AND VENTRICULAR FUNCTION DURING PTCA 
Table 1. Clinical Characteristics of 20 Study Patients 
Dipyridamole Conventional 
Pretreatment Pretreatment p 
(n = 10) (n = 10) Value 
Age (yr) 64.2 +_ 3.5 61.3 _+ 3.2 NS 
Male/female 9/1 9/1 
Extent of CAD 
1 VD 3 5 
2 VD 5 4 
3 VD 2 1 
Vessel dilated 
LAD 4 6 
LCx 3 2 
RCA 3 2 
Lesion site 
Proximal 5 6 
Mid 5 4 
Distal 0 0 
CABG 0 0 
% diameter stenosis 63.5 _+ 2.47 62.5 + 2.45 NS 
Data presented are mean value _+ SE or number of patients. CABG = 
coronary arte~, bypass graft surgery; CAD = coronary artery disease; LAD = 
left anterior descending coronary artery.; LCx = left circumflex coronary, artery; 
RCA = right coronan, artery; VD = vessel disease. 
procedure. Immediately before termination of balloon infla- 
tion, patients were asked to quantify the intensity of anginal 
pain as absent, little, moderate or severe. There were no 
significant differences with regard to oral antianginal medica- 
tion (dipyridamole pretreatment: itrates in six patients, beta- 
adrenergic blocking agents in seven, calcium channel antago- 
nists in two; conventional pretreatment: nitrates in seven 
patients, beta-blockers in five, calcium channel antagonists in 
four). Oral antianginal medication was discontinued at least 
12 h before angioplasty. All interventions were performed by 
the same investigator (B.E.S.) in the same catheterization 
laboratory. 
Statistical analysis. Results are expressed as mean value _+ 
SE. Data were analyzed by two-way repeated measures analy- 
sis of variance. For statistical analysis, only between-group 
comparison of hemodynamic variables (before PTCA vs. dur- 
ing PTCA and before PTCA vs. after PTCA) was performed. 
The Tukey test was applied for multiple comparisons of 
hemodynamic data. Statistical analysis was performed by 
means of PC-SAS software version 6.10. Significance was 
accepted at p < 0.05. 
Resu l ts  
Demographic data. Patients were randomly selected to 
receive either conventional pretreatment consisting of aspirin 
and heparin (nine men, one woman; mean age 61.3 + 3.2 
years, range 38 to 71) or additional pretreatment with dipyr- 
idamole (nine men, one woman; mean age 64.2 _+ 3.5 years, 
range 39 to 77, p = NS) before PTCA (Table 1). The 
dipyridamole group included five patients with two-vessel 
disease and two patients with three-vessel disease (mean 
diameter stenosis of non-PTCA arteries 52.3 _+ 2.9%; five 
proximal, one mid and three distal lesions). The conventional 
pretreatment group included four patients with two-vessel 
disease and one patient with three-vessel disease (mean diam- 
eter stenosis of non-PTCA arteries 55.8 _+ 3.4%; three proxi- 
mal, two mid and one distal lesion). 
Global and regional ejection fraction and volumes. Dipyr- 
idamole pretreatment prevented significant reduction of global 
ejection fraction (Fig. 1) during PTCA (68.0 -+ 4.0% vs. 68.1 _ 
3.7%), which could be documented in patients receiving con- 
ventional pretreatment (77.2 _+ 2.3% vs. 54.6 _+ 3.1%, p < 
0.01). After termination of balloon inflation, dipyridamole 
induced a significant increase in global ejection fraction of 
79.9 - 1.7% compared with conventional pretreatment (p < 
0.01). The reduction of global ejection fraction in patients 
receiving conventional pretreatment (Table 2) was due to a 
significant increase in end-systolic volume during PTCA 
(20.1 _+ 2.3 vs. 44.6 - 4.3 ml/m2), whereas end-systolic volume 
in patients receiving dipyridamole was not altered significantly 
during PTCA (p < 0.01) and was significantly lower after 
PTCA (p < 0.05). In dipyridamole-pretreated patients, frac- 
tional shortening in the jeopardized area was reduced uring 
PTCA (from 0.44 _+ 0.05% to 0.29 _+ 0.05%) and reached 
maximal values after termination ofPTCA (0.52 _+ 0.05%). In 
conventional pretreatment, reduction of fractional shortening 
was more dramatic (from 0.54 + 0.06% to 0.15 _+ 0.02%, p < 
0.05), and baseline values were only slightly augmented after 
PTCA (0.57 _+ 0.04%, p = NS). In the nonjeopardized area, 
dipyridamole induced a compensatory increase in fractional 
shortening (from 0.41 _+ 0.04% to 0.51 __ 0.05%), with further 
augmentation to 0.56 z 0.03% after balloon deflation. In 
conventional pretreatment, no significant alteration in frac- 
tional shortening in the nonjeopardized area could be docu- 
mented (0.45 _+ 0.03% before PTCA vs. 0.43 _+ 0.03% during 
PTCA vs. 0.41 _+ 0.03% after PTCA), resulting in a significant 
increase in fractional shortening during (p < 0.05) and after 
PTCA (p < 0.01) by dipyridamole. 
Isovolumetric phase indexes and indexes of contractility. 
In patients receiving conventional pretreatment, a dramatic 
reduction of MNSER and P syst/ESV could be seen during 
PTCA, whereas dipyridamole prevented a significant deterio- 
ration. After termination of balloon inflation, a significant 
increase in VCF, MNSER and P syst/ESV compared with 
baseline values was achieved by dipyridamole. A significant 
reduction i  dP/dt max and dP/dt mardIP during PTCA (Table 
3) could be prevented by intracoronary dipyridamole; dP/dt 
max was reduced by conventional treatment from 1,721 + 106 
to 1,402 _+ 89 mm Hg/s, whereas dipyridamole pretreatment 
caused only a moderate, insignificant reduction, from 1,503 _+ 
74 to 1,410 = 79 mm Hg/ml (p < 0.05). 
Indexes of diastolic function and wall stress. Independent 
of pretreatment used, no significant difference in the increase 
of LVEDP and diastolic wall stress was observed during 
PTCA. Dipyridamole prevented a significant increase in dia- 
stolic stiffness dP/dV (Fig. 2) that occurred in patients receiv- 
ing conventional therapy during PTCA (0.233 _ 0.019 vs. 
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Figure 1. End-systolic left ventricular ngiograms before (A) and 
during (B) PTCA of the left anterior descending coronary artery in a 
56-year old patient receiving conventional pretreatment and before 
(C) and during (D) PTCA of the left anterior descending coronary. 
artery in a 64-year old patient receiving dipyridamole pretreatment. 
0.267 _+ 0.016 mm Hg/ml, p < 0.01) and was fbllowed by a 
significant reduction after performance of PTCA (0.16 _+ 
0.012 mm Hg/ml, p < 0.01) compared with baseline values. 
During the interventional procedure, no significant alteration 
of end-systolic wall stress was noted. 
Blood pressure, heart rate, arrhythmias, ST segment shift 
and balloon inflation time. Independent of pretreatment 
used, no significant alteration of arterial blood pressure and 
heart rate could be documented (Table 4). Dipyridamole itself 
induced an insignificant lowering of systolic blood pressure 
from 146.9 _+ 4.6 to 138.3 _+ 3.8 mm Hg, accompanied by a 
transient increase in heart rate (77.9 _+ 4.6 vs. 83.5 _+ 6.1 
beats/rain), whereas diastolic blood pressure was not altered 
(69.3 _ 2.9 vs. 68.9 _+ 3.2 mm Hg). In one patient, dipyrida- 
mole pretreatment was followed by moderate anginal pain, 
indicating coronary steal phenomenon. Severity of anginal 
pain, balloon inflation pressure and ST segment shift (dipyr- 
idamole pretreatment: 0.17 _+ 0.03 mV conventional pretreat- 
ment: 0.20 + 0.04 mV, p = NS) did not differ significantly. In 
the dipyridamole pretreatment group, two patients developed 
ventricular premature beats during balloon inflation; one 
patient demonstrated premature atrial complexes. After con- 
ventional pretreatment, five patients presented with ventricu- 
lar premature beats, with one additional patient developing 
ventricular tachycardia. In one patient, premature atrial beats 
were noted. Dipyridamole pretreatment i duced a significant 
prolongation of tolerated balloon inflation time of 48.4% 
(205.1 _+ 7.2 s vs. 138.2 + 6.7 s, p < 0.01). 
Discuss ion  
Study results. These data indicate that preinterventional 
treatment with dipyridamole r sults in a marked preservation 
of left ventricular function and hemodynamic variables: 1) 
global eft ventricular function is mostly preserved; 2) regional 
ischemic left ventricular function deteriorates to a highly 
significant lesser extent, whereas regional left ventricular func- 
tion in the nonjeopardized area is augmented; 3) isovolumetric 
indexes are not altered significantly; 4) diastolic properties are 
affected less dramatically than in patients treated convention- 
ally. 
Implications for local drug delivery. This study used intra- 
coronary infusion of dipyridamole. Apart from one patient 
who experienced moderate anginal pain due to coronary steal 
phenomenon, o significant side effects were noted. Systolic 
blood pressure was lowered insignificantly, accompanied bya 
transient increase in heart rate. Baseline values were reestab- 
lished in <4 rain, indicating that these transient hemodynamic 
alterations had no influence on the subsequent response to 
ischemia. Dipyridamole administered intravenously is accom- 
panied by a relatively high rate of side effects (e.g., blood 
pressure decrease, increase in heart rate) and plasma protein 
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Table 2. Indexes of Volume, Contractility., Global Left Ventricular Ejection Fraction and Wall Stress* 
Dipyridamole Pretreatment Conventional Pretreatment 
Before During After Before During After 
PTCA PTCA PTCA PTCA PTCA PTCA 
EDV (ml/m 2) 
Mean 90.7 99.5 95.4 88.9 97.5 91.4 
SE 5.9 5.4 5.3 5.0 5.0 7.6 
p value NS NS 
ESV (ml/m z) 
Mean 29.4 31.8 18.8 20.1 44.6 21.3 
SE 4.7 4.7 1.4 2.3 4.3 2.9 
p value <0.01 <0.(/5 
EF (%) 
Mean 68.0 68.1 79.9 77.2 54.6 76.3 
SE 4.0 3.7 1.7 2~3 3.1 2.9 
p value <0.(11 <0.01 
VCF (circ/s) 
Mean 1.3 1.05 1.97 1.21 0.59 1.2 
SE (I.21 0.19 (/.22 0.1 0.08 0.09 
p value NS <0.05 
MNSER (vol/s) 
Mean 1.66 1.66 1.96 1.97 1,38 1.97 
SE 0.1 0.1 0.07 0.05 0,06 0.06 
p value <0.01 <0.01 
T syst (1,000 dynes/cm 2) 
Mean 333.7 293.1 345.1 309.3 292,3 289.1 
SE 14.9 21.5 16.6 18.5 16.6 20.9 
p value NS NS 
T diast (1,000 dynes/cm 2) 
Mean 35.0 46.7 29.4 25.4 45.1 28.9 
SE 3.8 3.9 2.6 3.0 6.9 3.1 
p value NS <0.01 
*Significance is defined as p < 0.05 and analyzed as between-group comparison related to baseline values 
(before percutaneous transluminal coronary, angioplasty [PTCA] vs. during PTCA and before PTCA vs. after PTCA). 
circ - circumference; EDV - end-diastolic volume; EF = global ejection fraction; ESV - end-systolic volume; 
MNSER -mcan normalized systolic ejection ratio; Y diast - end-diastolic wall stress; T syst end-systolic wall stress; 
VCF velocity of circumferential fiber shortening. 
binding, thus preventing sulficient local concentration. Intra- 
coronary, infusion of dipyridamole does not result in these side 
effects (12); moreover, it is most likely essential for induction 
of myocardial protection. 
Postulated mechanism of action. Dipyridamole inhibits the 
cellular uptake (erythrocyte, ndothelial cell) and degradation 
of adenosine, increasing its interstitial concentration. After 
binding to adenosine-A1 receptors (16), a pharmacologic 
cascade (17) is initiated. As a consequence of dipyridamole- 
induced preservation of left ventricular function, myocardial 
protection is achieved. Dipyridamole induced preservation of 
left ventricular function in the ischemic zone and, furthermore, 
exhibited a compensatory increase in fractional shortening in 
the nonjeopardized regions during and after PTCA. Thus, left 
ventricular function also improved regionally outside the dis- 
tribution of the ischemic area, indicating that improvement of
myocardial performance also occurs outside the jeopardized 
zone (18). This effect is presumably due to increased blood 
flow by dipyridamole. The beneficial effect of intracoronary 
dipyridamole can only be obtained when dipyridamole-induced 
myocardial protection prevails over PTCA-induced ischemia. 
After a mismatch between ischemia and myocardial protec- 
tion, left ventricular performance cannot be preserved in 
severe ischemia such as induced by PTCA of dominant vessels. 
Norepinephrine is released by efferent sympathetic nerves 
during ischemia (19). Its liberation can be inhibited by aden- 
osine (20). Blockade of adenosine receptors enhances the 
liberation of norepinephrine, thus facilitating arrhythmias (21) 
and further compromizing the jeopardized myocardium (22). 
Furthermore, affection of potassium and calcium channels 
results in calcium overload of the ischemic myocardinm. 
Reperfusion after PTCA is accompanied by a liberation of free 
radicals and lactate (23). Enhancement of adenosine during 
ischemia therefore might inhibit calcium overload of the 
myocardium and induce a scavenger effect (24) on free radi- 
cals. Activation of cardiac adenosine-A1 receptors by intra- 
coronary dipyridamole infusion thus might result in reduction 
of noradrenalin release, enhancement of tolerance to ischemia, 
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Table 3. Isovolumetric Phase Indexes, Diastolic Stiffness and Tension Time Index* 
Dipyridamole Pretreatment Conventional Pretreatment 
Before During After Before During After 
PTCA PTCA PTCA PTCA PTCA PTCA 
P syst/ESV (mm Hg/ml per m 2) 
Mean 5 4.29 7.21 7.35 3.15 6,43 
SE 0.51 0.44 0.68 0.81 0.42 0,71 
p value <0.05 <0.01 
dP/dt max (mm Hg/s) 
Mean 1,503 1,410 1526 1,721 1,402 1554 
SE 74 79 85 106 89 62 
p value <0.05 NS 
dP/dt min (ram H&"s) 
Mean 1,357 1,295 1,384 1,632 1,345 1,482 
SE 71 75 68 78 67 65 
p value NS NS 
dP/dt max/IP (I/s) 
Mean 37.6 35.3 38.2 43.0 35.0 38.9 
SE 1.9 2.0 2.1 2.7 2.2 1.6 
p value <0.05 NS 
dP/dV (ram Hg/ml) 
Mean 0.233 0.267 0.16 0.167 0.391 0.192 
SE 0.019 0.016 0.012 0.021 0.095 0.024 
p value <0.01 <0.01 
TI'I (P syst X HR) 
Mean 10,386 9,367 10,993 10,918 9,577 10,138 
SE 421 701 509 1,030 890 1,115 
p value NS NS 
*Significance defined as p < 0.05 and analyzed as between-group comparisons related to baseline values (before 
percutaneous transluminal coronary angioplasty [PTCA] vs. during PTCA and before PTCA vs. after PTCA). dP/dt 
max = maximal rate of increase of left ventricular pressure; dP/dt max/IP = dP/dt max at a developed pressure of 
40 mm Hg; dP/dt min = minimal rate of decline of left ventricular pressure; dP/dV = diastolic stiffness; F syst/ESV = 
systolic arterial pressure divided by end-systolic volume; P syst x HR = systolic arterial pressure times heart rate; TrI = 
tension time index. 
prevention of calcium accumulation a d reduction of arrhyth- 
mias (25) and energy imbalance (26). During baseline condi- 
tions, adenosine xerts no impact on contractility. During 
ischemia, adenosine stablishes an antiadrenergic effect, ac- 
Figure 2. Effect of PTCA on diastolic stiffness (dP/dV) according to
pretreatment dipyridamole (solid bars) or conventional (hatched 
bars). *p < 0.01, between-group comparison a d related to before 
PTCA, with significance d fined as p < 0.05. 




0 ,3 - -  
0.2 - -  
0 ,1 - -  
before PTCA during PTCA after PTCA 
companied by a reduction in myocardial oxygen demand and 
an improvement of oxygen supply to the ischemic and non- 
jeopardized myocardium (18) (stimulation of adenosine-A2 
receptors). Because of its antiadrenergic effects, intracoronary 
dipyridamole infusion can contribute to a reduction in the 
catecholamine-mediated increase in myocardial oxygen de- 
mand. This effect can be achieved by direct stimulation of 
adenosine-A1 receptors, as well as by stimulation of presynap- 
tic adenosine-A1 receptors, thus inhibiting release of cat- 
echolamines. 
The beneficial effect of dipyridamole on global and regional 
left ventricular systolic performance can be attributed to 1) 
enhancement of coronary perfusion (27,28), especially in the 
nonjeopardized region, as induced by dipyridamole "garden 
hose effect" (29), may exert a positive inotropic effect; 2) a 
direct positive inotropic effect of dipyridamole cannot be 
excluded; 3) reduction of systemic afterload with consecutive 
reduction of systolic wall stress and enhancement of ejection 
fraction in the ischemic and in the nonjeopardized region 
might be of importance; 4) improvement of myocardial ener- 
getics (26) as a result of adenosine nhancement in the 
ischemic area may occur; and 5) reduction of myocardial 
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Table 4. Hemodynamic Variables and Balloon Inflation Time* 
Dipyridamole Conventional 
Pretreatment Pretreatment 
Before During After Before During After 
PTCA PTCA PTCA PTCA PTCA PTCA 
























136.4 135.6 147.8 140.7 136.9 
6.9 5.9 8.8 6.9 8.2 
NS NS 
73 67.2 82.5 84.3 77.4 
3.3 2.5 4.6 4.7 4.3 
NS NS 
92.4 93.3 104.3 103.1 97.2 
4.1 3.4 5.9 4.9 5.1 
NS NS 
80.8 83.7 78.2 77.5 77.7 
3.7 3.3 5.2 5.6 5.3 
NS NS 
18.8 13.9 11.2 18.5 12.3 





*Significance defined as p < 0.05 versus baseline values. HR heart rate; 
LVEDP = left ventricular end-diastolic pressure; MAP = mean arterial blood 
pressure; P diast = diastolic arterial blood pressure: P syst - systolic arterial 
blood pressure; PTCA = percutaneous transluminal coronary angioplasty. 
calcium accumulation after dipyridamole infusion may play a 
role. 
Another potential mechanism refers to the possible recruit- 
ment of collateral channels by dipyridamole. Despite the 
failure of angiography to document collateral circulation, a 
vasoactive ffect of intracoronary dipyridamole on preexisting 
collateral vessels cannot be completely excluded. Opening of 
collateral vessels with consecutive improvement of the oxygen 
supply to the jeopardized myocardium ight induce a benefi- 
cial action on left ventricular performance, thus mimicking the 
postulated effect of myocardial protection. At present, it is not 
yet possible to quantify the potential effect of improved 
collateral circulation and to differentiate it from the pro- 
claimed induction of myocardial preconditioning. 
Intracoronary dipyridamole infusion induces a less pro- 
nounced iastolic dysfunction during PTCA, as documented by 
diastolic stiffness, indicating that diastolic dysfunction and its 
negative ffect on systolic function can be attenuated uring 
PTCA. Apart from a dipyridamole-induced protection of the 
ischemic myocardial segments, this phenomenon can be attrib- 
uted to an accelerated restorage of the cardiac adenosine 
triphosphate pool. Further explanations include inhibition of 
adenosine transport and improvement of microvascular perfu- 
sion. These effects are comparable to the role of adenosine in 
the setting of the stunned myocardium (30,31). 
Potential methodologic limitations. One hemodynamic 
limitation of this study is the use of fluid-filled catheters 
(pigtail) for evaluation of isovolumetric ndexes. However, all 
the indexes (isovolumetric, auxotonic ejection phase indexes) 
analyzing contractility demonstrated comparable and similar 
changes during PTCA, indicating that miscalculation can be 
characterized as negligible. Furthermore, additional quantifi- 
cation of pressure-independent contractile indexes (VCF, 
MNSER, ejection fraction, P syst/ESV) demonstrated the 
favorable effects of dipyridamole use. Due to the uniform 
augmentation of hemodynamic variables, dipyridamole use 
induces significant improvement of left ventricular perfor- 
mance. 
Baseline values of global ejection fraction, MNSER, end- 
diastolic wall stress, P syst/ESV, dP/dt rain, dP/dV, diastolic 
arterial blood pressure and LVEDP differed significantly (p < 
0.05) in patients receiving conventional pretreatment versus 
those receiving dipyridamole. Dipyridamole-pretreated pa-
tients presented with lower baseline values for ejection frac- 
tion, MNSER, P syst/ESV, dP/dt rain and diastolic arterial 
pressure and higher values for end-diastolic wall stress, dP/dV 
and LVEDP. Because of the uniform improvement of hemo- 
dynamic variables during intracoronary dipyridamole, misin- 
terpretation of values during and after PTCA as a result of 
different baseline values can be considered negligible. 
Analysis of our data shows that dipyridamole seems to exert 
a positive influence on balloon inflation time tolerated by the 
patients. However, our study was not performed in double- 
blind manner, resulting in a possible bias on the part of the 
investigator performing the PTCA. For this reason, an in- 
creased tolerance to ischemia by intracoronary dipyridamole, 
as indicated by a prolonged balloon-inflation time, cannot be 
proved by our data. 
Clinical implications. With regard to mechanism of action, 
intracorona~ infusion of dipyridamole seems to prove the 
central role of adenosine in the setting of ischemic precondi- 
tioning. With regard to its therapeutic mplications, myocardial 
protection with a consecutive r duction in ischemic complica- 
tions seems to play a central role. 
Summary. Dipyridamole infusion induces a significant 
amelioration of global and regional left ventricular perfor- 
mance during ischemia. Diastolic dysfunction during PTCA is 
reduced markedly by dipyridamole. Apart from one patient 
who experienced moderate anginal pain, no significant side 
effects of dipyridamole medication could be detected. 
References 
1. Lawson CS, Downey JM. Preconditioning: state of the art myocardial 
protection. Cardiovasc Res 1993;27:542-50. 
2. Murry' CE, Jennings RB, Reimer KA. Preconditioning with ischemia: adelay 
of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36. 
3. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with 
preconditioning. Circulation 1990;82:609-19. 
4. Miura T. Ogawa T, lwamoto T, Shimamoto K, Iimura O. Dipyridamole 
1126 STRAUER ET AL. JACC Vol. 28, No. 5 
DIPYRIDAMOLE AND VENTRICULAR FUNCTION DURING PTCA November 1, 1996:1119-26 
potentiates the myocardial infarct-size-limiting effect of ischemic precondi- 
tioning. Circulation 1992;86:979-85. 
5. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital 
outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 
1995;91:37-47. 
6. Van der Heide RS, Reimer KA, Jennings RB. Adenosine slows ischemic 
metabolism incanine myocardium in vitro: relationship to ischemic precon- 
ditioning. Cardiovasc Res 1993;27:669-73. 
7. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? 
J Am Coil Cardiol 1994;24:1133-42. 
8. Strauer BE. The significance of coronary reserve in clinical heart disease. 
J Am Coil Cardiol 1990;15:775-83. 
9. Fitzgerald GA. Drug therapy: dipyridamole. New Engl J Med 1987;316: 
1247-57. 
10. Kiibler W. Die Bindung des Kornnardilatators Dipyridamol an die Plasmaei- 
weiBk6rper des Menschen. Arch Krcislaufforseh 1971;64:115-26. 
11. K~bler W, Spieckermann PG, Bretschneider HJ. Influence of dipyridamole 
(Persantin) on myocardial adenosine metabolism. J Mol Cell Cardiol 
1970;1:23-37. 
12. Strauer BE, Heidland UE, Vogt M, Schwartzkopff B,Heintzen MP. Protcktion 
und "Preconditioning" des menschlichcn Herzens w/ihrend perkutaner translu- 
minaler coronarangioplastie (PTCA) dutch intrakoronare Dipyridamol- 
Applikation. Med Kiln 1995;90:125-30. 
13. Prachar H. Ver~inderungen w/ihrend PTCA: cin Modell der Isch/imie am 
Menschen. Acta Med Austriaca 1991;18 Suppl 42:1-35. 
14. Heintzen MP, Motz W, Leschke M, et al. PTCA im Stadium des akuten 
Myokardinfarktes: Hospitalverlauf yon 785 konsekutiven Patienten. Z Kar- 
diol 1994;83:404-13. 
15. Strauer BE. The Heart in Hypertension. 3rd ed. Berlin: Springer-Verlag, 
199l :$34. 
16. B6hm M, Meyer W, M/igge A, Schmitz W, Scholz H. Functional evidence for 
the existence of adenosine receptors in the human heart. Eur J Pharmacol 
1985;116:323-6. 
17. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990; 
70:761-845. 
18. Przyldenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 
preconditioning protects remote virgin myocardium from subsequent sus- 
tained coronary occlusion. Circulation 1993;87:893-9. 
19. Seh0mig A, Fischer S, Kurz T, Richardt G, SchOmig E. Nonexocytotic 
release of endogenous noradrenaline in the ischemic and anoxic rat heart: 
mechanism and metabolic requirements. Circ Res 1987;60:194-205. 
20. Richardt G, Waas W, Kranzhofer R, Mayer E, Sch6mig A. Adenosine 
inhibits exocytotic release of endogenous noradrenaline in rat heart: a 
protective mechanism in early myocardial ischemia. Cire Res 1987;61:112 
23. 
21. Lombardi F, Verrier LR, lJown B. Relationship between sympathetic neural 
activi~', coronary dynamics and vulnerability to ventricular fibrillation during 
myocardial ischemia nd repeffusion. Am Heart J 1983;105:958-65. 
22. Neely JR, Gro~ohann LW. Role of glycolytic products in damage to 
ischemic myocardium: dissociation of adenosine triphosphate l vels and 
recovery of function of reperfused ischemic hearts. Circ Res 1984;55:816-24. 
23. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey 
WK. Adaption to ischemia during percutaneous transluminal coronary 
angioplasty: clinical, hemodynamic and metabolic features. Circulation 
1990;82:2044-51. 
24. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a
physiological modulator of superoxide anion generation by human neutro- 
phils. J Exp Med 1983;158:1160-77. 
25. Parratt J, Vegh A. Pronounced antiarrhythmic effects of ischemic precondi- 
tioning. Cardioscience 1994;5:9-18. 
26. Van Wylen DG. Effect of ischcmic preconditioning on interstitial purine 
metabolite and lactate accumulation during myocardial ischemia. Circula- 
tion 1994;89:2283-9. 
27. Cox DA, Vita JA, Treasure CB, Fish RD, Selwyn AP, Ganz P. Reflex 
increase in blood pressure during the intraeoronary administration of 
adenosine in man. J Clin Invest 1989;84:592-6. 
28. Gregg DE. Effect of coronary perfusion pressure or coronary, flow on oxygen 
usage of the myocardium. Circ Res 1963;13:497-500. 
29. May-Newman K, Omens JH. Pavelec RS, McCulloch AD. Three dimen- 
sional transmural mechanical interaction between the coronary vasculature 
and passive myocardium in the dog. Circ Res 1994;74:1166-78. 
30. Braunwald E, Kloner RA. The stunned myocardium: prolonged postisch- 
emie ventricular dysfunction. Circulation 1982;60:1146-9. 
31. De Boer LWV, Ingwall JS, Kloner RA, Braunwald E. Prolonged erange- 
ments of canine myocardial purine metabolism after a brief coronary artery 
occlusion not associated with anatomic evidence of necrosis. Proc Natl Acad 
Sci USA 1980;77:5471-5. 
